Publication | Closed Access

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study

Translational MedicinePharmacodynamic End PointsPharmacologyRadiopharmaceutical TherapyPharmacotherapyMedicineRadiation OncologyPharmacokineticsPharmacodynamic ModelingFractionated Radiotherapy